Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anatomy of the Genitourinary System II: Bladder and Urethra01:19

Anatomy of the Genitourinary System II: Bladder and Urethra

1.1K
The lower urinary system consists of the urinary bladder and urethra, which are essential in storing and expelling urine from the body. Together with the internal and external sphincters, these structures work together to regulate urination effectively.Anatomy of the BladderThe urinary bladder is a muscular, stretchable organ behind the pubic bone and in front of the rectum. In females, the bladder is positioned anterior to the vagina and inferior to the uterus, while in males, it is located...
1.1K
Urinary Tract Calculi III: Medical Management01:30

Urinary Tract Calculi III: Medical Management

154
The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
154
Urinary Bladder01:23

Urinary Bladder

2.9K
The urinary bladder is a hollow, muscular sac that temporarily stores urine before it is expelled from the body. It can hold approximately 600 mL of urine prior to micturition. The bladder is retroperitoneal and located behind the pubic symphysis in the pelvic floor.
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...
2.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in patients with high body mass index or diabetes mellitus.

ESMO open·2026
Same author

Clinical validation of liquid biopsy-RECIST (LB-RECIST) in metastatic colorectal cancer (mCRC) patients: findings from the PLATFORM-B study.

ESMO open·2025
Same author

Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients.

ESMO open·2025
Same author

Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial.

ESMO open·2024
Same author

Maintenance with 5-FU/LV-aflibercept after induction with FOLFIRI-aflibercept versus FOLFIRI-aflibercept until progression as second-line treatment in older adults with metastatic colorectal cancer: the AFEMA phase II randomized trial.

ESMO open·2024

Related Experiment Video

Updated: Jan 4, 2026

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

13.0K

New agents for bladder cancer.

J Bellmunt1, M Guix

  • 1University Hospital del Mar, Barcelona, Spain. jbellmunt@imas.imim.es

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|October 15, 2010
PubMed
Summary

Muscle-invasive bladder cancer is aggressive, with poor survival rates. New targeted therapies and improved patient selection strategies show promise for overcoming current treatment limitations in advanced bladder cancer.

Area of Science:

  • Oncology
  • Cancer Research

Background:

  • Muscle-invasive bladder cancer (MIBC) is an aggressive malignancy with high metastatic potential.
  • Current 5-year survival rates for metastatic bladder cancer are below 15%, indicating a significant unmet need.
  • While chemotherapy has improved survival, further advancements are crucial for better patient outcomes.

Purpose of the Study:

  • To review emerging therapies and strategies for advanced bladder cancer.
  • To highlight novel agents targeting key oncogenic pathways.
  • To discuss the potential of improved patient and treatment selection.

Main Methods:

  • Review of recent and ongoing clinical trials in advanced bladder cancer.
  • Analysis of novel therapeutic agents targeting growth factor receptors, angiogenesis, p53, cell cycle, and apoptosis.

More Related Videos

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.6K
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

15.1K

Related Experiment Videos

Last Updated: Jan 4, 2026

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

13.0K
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.6K
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

15.1K
  • Examination of strategies for patient and treatment selection.

    • Main Results:

    • New therapeutic agents targeting critical cancer pathways are under investigation.
    • Ongoing trials are evaluating novel chemotherapeutic agents and targeted therapies.
    • Emerging data suggests these novel approaches may offer improved efficacy.

    Conclusions:

    • Significant opportunities exist to improve outcomes for patients with advanced bladder cancer.
    • Targeted therapies and novel agents show promise in overcoming current treatment limitations.
    • Future research focuses on personalized medicine approaches for bladder cancer treatment.